The US biotech company said the trial had shown its vaccine to be also 93% effective against circulating variants of concern and variants of interest, and 91% effective in protecting high-risk populations.
The trial, which involved 29,960 participants at 119 sites in the United States and Mexico, showed an overall effectiveness of 90.4%.
The study emphasized having participants who represented the communities and demographics most affected by the disease.
COVID updates live from UK and around the world
Within the group, 77 people tested positive for COVID-19, 63 were on placebo and 14 had received the vaccine.
All cases in the vaccinated group were defined as “mild” while 10 “moderate” and four “severe” cases were observed among those who received the placebo.
Preliminary safety data from the study also showed that “usually mild to moderate” pain and tenderness around the injection site, as well as fatigue, muscle aches, and headaches were the most common symptoms. common among participants.
Gregory Glenn, President of Research and Development at Novavax, said: “Our vaccine will be an essential part of the solution for COVID-19[feminine[feminine and we are grateful to the study participants and trial staff who made this study possible, as well as to our supporters, including the US government. “
The company remains on track to be able to manufacture 100 million doses of vaccine per month by the end of September and 150 million doses by the end of the year, once it receives approvals. regulatory.
Novavax President and CEO Stanley Erck said the results show this is “one step closer to meeting the critical and persistent global public health need” for COVID-19[feminine[feminine blows.
He added, “Novavax continues to work with a sense of urgency to complete our regulatory submissions and deliver this vaccine, built on a well-understood and proven platform, to a world that is still in dire need of vaccines. ”